Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$10.57 USD
+0.45 (4.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $10.53 -0.04 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Inovio Pharmaceuticals, Inc. [INO]
Reports for Purchase
Showing records 241 - 260 ( 363 total )
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Hold Response Submitted; VGX-3100 Phase 3 Trial Starting This Quarter; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2016 Financial Results Reported; VGX-3100 Phase 3 Trial Starting in 1H 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MERS and Zika Vaccines Advance in Phase 1 Trials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Zika Vaccine Produced Robust Immune Response in Phase 1 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q16 Financial Results; Reiterate Buy and Adjusting Price Target to $13
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 Trial of VGX-3100 Delayed to 1H 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.